Generic Name: budesonide
Brand Name: Jorveza
Manufacturer: AVIR Pharma Inc.
Indications: Eosinophilic esophagitis, adults
Manufacturer Requested Reimbursement Criteria1: For the induction of clinico-pathological remission in adults with eosinophilic esophagitis (EoE), as per Health Canada indication
Submission Type: New
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient input posted | September 03, 2019 |
| Patient group input closed | October 23, 2019 |
| Clarification: - Patient input submission received from AEDESEO, American Partnership for Eosinophilic Disorders, ausEE Inc., CURED foundation, Gastrointestinal Society and FABED Families Affected by Eosinophilic Disorder | |
| Patient input summary sent for review to patient input groups | December 04, 2019 |
| Patient group comments on input summary closed | December 11, 2019 |
| Clarification: - Patient input summary feedback received | |
| Submission received | November 08, 2019 |
| Submission accepted | November 22, 2019 |
| Review initiated | November 25, 2019 |
| Clarification: - Selected for CADTH/INESSS Joint Clinician Engagement - Submission temporarily suspended pending receipt of information - Additional information has been received and the temporary suspension of the review has been lifted | |
| Draft CADTH review report(s) sent to sponsor | March 24, 2020 |
| Comments from sponsor on draft CADTH review report(s) received | April 02, 2020 |
| CADTH review team's comments on draft CADTH review report(s) sent to sponsor | May 07, 2020 |
| Canadian Drug Expert Committee (CDEC) meeting | May 20, 2020 |
| CDEC recommendation sent to sponsor and drug plans | June 01, 2020 |
| Embargo period ended | June 15, 2020 |